DE2415812A1 - Poly(5-hydroxycytidylsaeuren) - Google Patents
Poly(5-hydroxycytidylsaeuren)Info
- Publication number
- DE2415812A1 DE2415812A1 DE2415812A DE2415812A DE2415812A1 DE 2415812 A1 DE2415812 A1 DE 2415812A1 DE 2415812 A DE2415812 A DE 2415812A DE 2415812 A DE2415812 A DE 2415812A DE 2415812 A1 DE2415812 A1 DE 2415812A1
- Authority
- DE
- Germany
- Prior art keywords
- poly
- acid
- hydroxycytidylic
- hydroxycytidine
- acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000002253 acid Substances 0.000 title claims description 43
- 150000007513 acids Chemical class 0.000 title claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 10
- FRCPDDIIYSVHGB-UAKXSSHOSA-N [(2r,3s,4r,5r)-5-(4-amino-5-hydroxy-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound C1=C(O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 FRCPDDIIYSVHGB-UAKXSSHOSA-N 0.000 claims description 10
- MPPUDRFYDKDPBN-UAKXSSHOSA-N 4-amino-1-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-hydroxypyrimidin-2-one Chemical group C1=C(O)C(N)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 MPPUDRFYDKDPBN-UAKXSSHOSA-N 0.000 claims description 6
- 101001066878 Homo sapiens Polyribonucleotide nucleotidyltransferase 1, mitochondrial Proteins 0.000 claims description 5
- 102000002681 Polyribonucleotide nucleotidyltransferase Human genes 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- IHQKEDIOMGYHEB-UHFFFAOYSA-M sodium dimethylarsinate Chemical compound [Na+].C[As](C)([O-])=O IHQKEDIOMGYHEB-UHFFFAOYSA-M 0.000 claims description 4
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 claims description 2
- 238000004062 sedimentation Methods 0.000 claims description 2
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 description 30
- 239000002157 polynucleotide Substances 0.000 description 30
- 102000040430 polynucleotide Human genes 0.000 description 30
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 9
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 8
- 229910052794 bromium Inorganic materials 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- ZWIADYZPOWUWEW-XVFCMESISA-N CDP Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(O)=O)O1 ZWIADYZPOWUWEW-XVFCMESISA-N 0.000 description 5
- BWZVCCNYKMEVEX-UHFFFAOYSA-N 2,4,6-Trimethylpyridine Chemical compound CC1=CC(C)=NC(C)=C1 BWZVCCNYKMEVEX-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 241000710188 Encephalomyocarditis virus Species 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 241000710961 Semliki Forest virus Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- CXYZTGHGARBUGL-UAKXSSHOSA-N [(2R,3S,4R,5R)-5-(4-amino-5-bromo-2-oxopyrimidin-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphono hydrogen phosphate Chemical compound P(O)(=O)(OP(=O)(O)O)OC[C@@H]1[C@H]([C@H]([C@@H](O1)N1C(=O)N=C(N)C(=C1)Br)O)O CXYZTGHGARBUGL-UAKXSSHOSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 3
- AUHZEENZYGFFBQ-UHFFFAOYSA-N 1,3,5-Me3C6H3 Natural products CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 2
- XASWYPVFCVEQSU-UHFFFAOYSA-N 2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid;potassium Chemical compound [K].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O XASWYPVFCVEQSU-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- GFYHSKONPJXCDE-UHFFFAOYSA-N sym-collidine Natural products CC1=CN=C(C)C(C)=C1 GFYHSKONPJXCDE-UHFFFAOYSA-N 0.000 description 2
- 230000009385 viral infection Effects 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102000009097 Phosphorylases Human genes 0.000 description 1
- 108010073135 Phosphorylases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 241000710960 Sindbis virus Species 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- OFIHJYLASXZYAR-UHFFFAOYSA-N [Hg](=O)=O Chemical compound [Hg](=O)=O OFIHJYLASXZYAR-UHFFFAOYSA-N 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical group OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000007269 dehydrobromination reaction Methods 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 231100001264 fatal toxicity Toxicity 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000140 heteropolymer Polymers 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- AFQIYTIJXGTIEY-UHFFFAOYSA-N hydrogen carbonate;triethylazanium Chemical compound OC(O)=O.CCN(CC)CC AFQIYTIJXGTIEY-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 239000002799 interferon inducing agent Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000003189 isokinetic effect Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/811—Interferon
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1567173A GB1435571A (en) | 1973-04-02 | 1973-04-02 | Polynucleotides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2415812A1 true DE2415812A1 (de) | 1974-10-17 |
Family
ID=10063332
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE2415812A Withdrawn DE2415812A1 (de) | 1973-04-02 | 1974-04-01 | Poly(5-hydroxycytidylsaeuren) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US3935185A (enExample) |
| BE (1) | BE813201A (enExample) |
| CA (1) | CA1006871A (enExample) |
| DE (1) | DE2415812A1 (enExample) |
| DK (1) | DK134994B (enExample) |
| FR (1) | FR2223046B1 (enExample) |
| GB (1) | GB1435571A (enExample) |
| NL (1) | NL7404394A (enExample) |
| ZA (1) | ZA742062B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010135564A3 (en) * | 2009-05-20 | 2011-05-05 | Sena Research, Inc. | Novel compounds and derivatization of dnas and rnas on the nucleobases of pyrimidines for function, structure, and therapeutics |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2292481A1 (fr) * | 1974-11-26 | 1976-06-25 | Anvar | Nouveaux polynucleotides, leurs procedes de preparation, et medicaments a base de ces produits |
| GB1545099A (en) * | 1976-12-23 | 1979-05-02 | Searle & Co | Poly-5-hydroxycytidylic acid copolymers |
| GB8725606D0 (en) * | 1987-11-02 | 1987-12-09 | Soc D Etudes Prod Chimique | Preparation polynucleotides |
| GB9108085D0 (en) * | 1991-04-16 | 1991-06-05 | Scras | Complexes of polyadenylic acid with polyuridylic acid |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3462414A (en) * | 1966-08-08 | 1969-08-19 | Upjohn Co | Polymers of cytosine arabinoside phosphates |
| US3652538A (en) * | 1969-08-08 | 1972-03-28 | Pfizer | Formulation process for polynucleotide homopolymers |
-
1973
- 1973-04-02 GB GB1567173A patent/GB1435571A/en not_active Expired
-
1974
- 1974-03-28 US US05/455,877 patent/US3935185A/en not_active Expired - Lifetime
- 1974-04-01 DK DK180074AA patent/DK134994B/da unknown
- 1974-04-01 NL NL7404394A patent/NL7404394A/xx unknown
- 1974-04-01 DE DE2415812A patent/DE2415812A1/de not_active Withdrawn
- 1974-04-01 ZA ZA00742062A patent/ZA742062B/xx unknown
- 1974-04-02 BE BE142764A patent/BE813201A/xx unknown
- 1974-04-02 FR FR7411712A patent/FR2223046B1/fr not_active Expired
- 1974-04-02 CA CA196,598A patent/CA1006871A/en not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010135564A3 (en) * | 2009-05-20 | 2011-05-05 | Sena Research, Inc. | Novel compounds and derivatization of dnas and rnas on the nucleobases of pyrimidines for function, structure, and therapeutics |
Also Published As
| Publication number | Publication date |
|---|---|
| DK134994B (da) | 1977-02-21 |
| DK134994C (enExample) | 1977-07-11 |
| GB1435571A (en) | 1976-05-12 |
| FR2223046A1 (enExample) | 1974-10-25 |
| BE813201A (fr) | 1974-10-02 |
| CA1006871A (en) | 1977-03-15 |
| NL7404394A (enExample) | 1974-10-04 |
| FR2223046B1 (enExample) | 1977-01-28 |
| ZA742062B (en) | 1975-11-26 |
| US3935185A (en) | 1976-01-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2915254A1 (de) | Neue chemische verbindungen, verfahren zu deren herstellung und deren verwendung als arzneimittel mit antiviraler wirkung | |
| DE2451358A1 (de) | Verfahren zur herstellung von modifizierte ribonucleinsaeuremolekuele enthaltenden zusammensetzungen und diese zusammensetzungen | |
| WO2004037865A1 (de) | Wasserlösliche eisen-kohlenhydrat-komplexe, deren herstellung und diese enthaltende arzneimittel | |
| EP2137203B1 (de) | Ethinylierte heterodinucleosidphosphatanaloga, verfahren zu deren herstellung und deren verwendung | |
| DE3045078A1 (de) | Nucleasebestaendiger hydrophiler komplex aus polyriboinosinsaeure, verfahren zu seiner herstellung und verwendung desselben | |
| DE502588T1 (de) | Verfahren zur Amplifizierung von Nukleinsäuresequenzen. | |
| WO1992018520A1 (de) | Neue cytarabin-derivate, ihre herstellung und verwendung | |
| DE3543346A1 (de) | Neue nucleosidderivate und verfahren zu ihrer herstellung | |
| DE2051745A1 (de) | Von Nucleinsäuren stammende Arznei mittel und Verfahren zu ihrer Herstellung | |
| DE68904264T2 (de) | Fragmente und fraktionen von heparin mit wirkung gegen hiv. | |
| DE2415812A1 (de) | Poly(5-hydroxycytidylsaeuren) | |
| DE2546073A1 (de) | Nucleotid-derivate und verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln | |
| DE19855963A1 (de) | Amphiphile Glycerylnucleotide, Verfahren zu ihrer Herstellung und ihre Verwendung | |
| DE2658672A1 (de) | Neue nucleosid-verbindungen und verfahren zu ihrer herstellung | |
| DE2423811A1 (de) | Verfahren zur herstellung von gefriergetrockneten 2,2'-anhydro-1-beta-d-arabinofuranosylcytosin-praeparaten und injektionspraeparat | |
| DE2830901A1 (de) | Reaktionsprodukte von methotrexat und divinylaether-maleinsaeureanhydrid- copolymerisaten, verfahren zu ihrer herstellung und ihre verwendung | |
| DE2735455B2 (de) | Daunomycinanaloga, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel | |
| DE2359621C2 (de) | Antiviral wirksame Alkalimetall- oder Ammoniumsalze der Polyacrylsäure | |
| DE3515178A1 (de) | Verfahren zur herstellung von neuen anthracyclinkonjugaten anionischer polymerer | |
| CA1042877A (en) | Antiviral agents | |
| DE2626792A1 (de) | Acylderivate von adenosin-5'-monophosphorsaeure, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzung | |
| CH496003A (de) | Verfahren zur Herstellung von Aracytidinphosphaten | |
| DE1667897C2 (de) | Zytostatisch wirksame Mittel | |
| Grimberg et al. | In vitro transcription of E. coli tRNA genes | |
| CH671960A5 (enExample) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8141 | Disposal/no request for examination |